IMUOE
Imugene Limited
๐ฆ๐บ ASX
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
+ 34.51%
Annual Growth
1 years average annual growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
2
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Imugene Limited - Option Expiring 31-Aug-2026
๐ Performance
Price History
+37.50%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฐ Price*
$0.02
*Price may be up to 24 hours old
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in IMUOE
2
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in IMUOE
N/A
IMUOE investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
100%
๐ Legal gender of investors
Female
100%
Male
Pearlers who invest in IMUOE also invest in...
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyโs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
๐ Performance (5Yr p.a)
18.26%
๐ Share price
$0.04 AUD
๐งฌ BIOTECHNOLOGY
๐ HIGH PRICE GROWTH
Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 768 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australiaโs resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.
๐ Performance (5Yr p.a)
150.62%
๐ Share price
$3.02 AUD
โ๏ธ MINING
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
3.74%
๐ Share price
$66.58 AUD
๐ GLOBAL
โณ๏ธ DIVERSIFIED
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
๐ Performance (5Yr p.a)
9.39%
๐ Share price
$35.09 AUD
๐ฉบ HEALTH CARE
๐ฆ๐บ EX AUSTRALIA
๐ค TECHNOLOGY
๐ HIGH PRICE GROWTH
GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.
๐ Performance (5Yr p.a)
3.87%
๐ Share price
$31.53 AUD
๐ธ FINANCIALS
๐บ๐ธ EX UNITED STATES
๐ญ INDUSTRIALS
Want more shares? Try these...
Ingenia Communities Group engages in managing and developing a portfolio of retirement and lifestyle communities. The company is headquartered in Sydney, New South Wales and currently employs 1,300 full-time employees. The company went IPO on 2004-07-01. The company owns, operates, and develops a portfolio of lifestyle and holiday communities across key urban and coastal markets. The company operates in five segments: Lifestyle Development; Lifestyle Rental; Ingenia Gardens; Ingenia Holidays; and Fuel, Food & Beverage Services. The Lifestyle Development segment comprises of the development and sale of lifestyle homes. The Lifestyle Rental segment comprises of long-term accommodation within lifestyle and rental communities. The Ingenia Gardens segment consists of rental villages. The Ingenia Holidays segment comprises of tourism and rental accommodation within holiday parks. The Fuel, Food & Beverage Services segment consists of the Companyโs investment in service station and food & beverage operations adjoined to Ingenia Holiday communities. Its subsidiaries include Bridge Street Trust, Browns Plains Road Trust, Casuarina Road Trust, Edinburgh Drive Trust, and Garden Villages Management Trust.
๐ Performance (5Yr p.a)
1.60%
๐ Share price
$4.73 AUD
๐๏ธ SOCIALLY AWARE
๐ REAL ESTATE
INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income.
๐ Performance (5Yr p.a)
1.78%
๐ Share price
$17.99 AUD
๐ฆ๐บ EX AUSTRALIA
๐ UTILITIES
โณ๏ธ DIVERSIFIED
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The firm sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.
๐ Performance (5Yr p.a)
-6.70%
๐ Share price
$0.74 AUD
๐ฉบ HEALTH CARE
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyโs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
๐ Performance (5Yr p.a)
18.26%
๐ Share price
$0.04 AUD
๐งฌ BIOTECHNOLOGY
๐ HIGH PRICE GROWTH